Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers

Item

http://www.wikidata.org/entity/Q37057992

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers

@en

Association of HER2 Overexpression and Prognosis in Small

@nl

type

Item

label

Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers

@en

Association of HER2 Overexpression and Prognosis in Small

@nl

prefLabel

Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers

@en

Association of HER2 Overexpression and Prognosis in Small

@nl

P1476

Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers

@en

P2093

Christof Sohn

http://www.w3.org/2001/XMLSchema#string

Christoph Domschke

http://www.w3.org/2001/XMLSchema#string

Claudia Schumacher

http://www.w3.org/2001/XMLSchema#string

Frederik Marmé

http://www.w3.org/2001/XMLSchema#string

Joachim Rom

http://www.w3.org/2001/XMLSchema#string

Josef Höfler

http://www.w3.org/2001/XMLSchema#string

Oleg Gluz

http://www.w3.org/2001/XMLSchema#string

Sebastian Eidt

http://www.w3.org/2001/XMLSchema#string

Ulrike Nitz

http://www.w3.org/2001/XMLSchema#string

P2860

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer.

A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?

Predictors of recurrence in stage I (T1N0M0) breast carcinoma.

Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.

P304

208-214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000352094

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Schneeweiss

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24415972

http://www.w3.org/2001/XMLSchema#string

P921

overexpression

P932

3728630

http://www.w3.org/2001/XMLSchema#string